126 related articles for article (PubMed ID: 11429700)
1. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.
Maurici D; Monti P; Campomenosi P; North S; Frebourg T; Fronza G; Hainaut P
Oncogene; 2001 Jun; 20(27):3533-40. PubMed ID: 11429700
[TBL] [Abstract][Full Text] [Related]
2. Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast.
Grochova D; Vankova J; Damborsky J; Ravcukova B; Smarda J; Vojtesek B; Smardova J
Oncogene; 2008 Feb; 27(9):1243-52. PubMed ID: 17724467
[TBL] [Abstract][Full Text] [Related]
3. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
4. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
5. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
7. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
Inga A; Monti P; Fronza G; Darden T; Resnick MA
Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
[TBL] [Abstract][Full Text] [Related]
8. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
9. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1.
North S; Pluquet O; Maurici D; El-Ghissassi F; Hainaut P
Mol Carcinog; 2002 Mar; 33(3):181-8. PubMed ID: 11870884
[TBL] [Abstract][Full Text] [Related]
10. Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells.
Jagosova J; Pitrova L; Slovackova J; Ravcukova B; Smarda J; Smardova J
Int J Oncol; 2012 Sep; 41(3):1157-63. PubMed ID: 22710932
[TBL] [Abstract][Full Text] [Related]
11. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity.
Resnick MA; Inga A
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9934-9. PubMed ID: 12909720
[TBL] [Abstract][Full Text] [Related]
12. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
Brazda V; Muller P; Brozkova K; Vojtesek B
Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
[TBL] [Abstract][Full Text] [Related]
13. Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions.
Stavridi ES; Chehab NH; Caruso LC; Halazonetis TD
Protein Sci; 1999 Sep; 8(9):1773-9. PubMed ID: 10493578
[TBL] [Abstract][Full Text] [Related]
14. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro.
Hainaut P; Milner J
Cancer Res; 1993 Oct; 53(19):4469-73. PubMed ID: 8402615
[TBL] [Abstract][Full Text] [Related]
15. p53 mutants without a functional tetramerisation domain are not oncogenic.
Chène P; Bechter E
J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.
Cardellino U; Ciribilli Y; Andreotti V; Modesto P; Menichini P; Fronza G; Pellegrino C; Inga A
Mutagenesis; 2007 Nov; 22(6):417-23. PubMed ID: 17947339
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
Chen JY; Funk WD; Wright WE; Shay JW; Minna JD
Oncogene; 1993 Aug; 8(8):2159-66. PubMed ID: 8336941
[TBL] [Abstract][Full Text] [Related]
18. Restoration of the transcription activation function to mutant p53 in human cancer cells.
Abarzúa P; LoSardo JE; Gubler ML; Spathis R; Lu YA; Felix A; Neri A
Oncogene; 1996 Dec; 13(11):2477-82. PubMed ID: 8957091
[TBL] [Abstract][Full Text] [Related]
19. Loss of TP53-DNA interaction induced by p.C135R in lung cancer.
Aranda M; Gonzalez-Nilo F; Riadi G; Díaz V; Perez J; Martel G; Hainaut P; Mimbacas A
Oncol Rep; 2007 Nov; 18(5):1213-7. PubMed ID: 17914575
[TBL] [Abstract][Full Text] [Related]
20. Reporter gene regulation in Saccharomyces cerevisiae by the human p53 tumor suppressor protein.
Bitter GA; Schaeffer TN; Ellison AR
J Mol Microbiol Biotechnol; 2002 Nov; 4(6):539-50. PubMed ID: 12432954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
